Decipher Biosciences is one of five new startup companies being supported by Bayer as part of its G4A Digital Health Partnerships Program.
Decipher Biosciences offers a portfolio of genomic tests, is building the GRID database of over 85,000 whole transcriptome profiles, and is partnering with pharmaceutical companies to identify biomarkers of response to novel therapeutics.
The focus will be on fostering the development of a digital health ecosystem, while driving forward integrated healthcare solutions in the fields of cardiometabolic and renal diseases, oncology, and women’s health. The participating digital healthcare companies were selected by Bayer from over 400 applications from over 65 countries based upon current and future strategic fit, development stage and assessment.
“Building new digital business models is a key element of Bayer’s business strategy, with the ambition to actively shape the future of healthcare. We are proud to support startups who share our vision of integrated healthcare solutions that put the patient in focus, not the disease,” said Jeanne Kehren, Head of Digital & Commercial Innovation and Member of the Pharmaceuticals Executive Committee of Bayer.
Bayer’s G4A partnership program offers two digital health collaboration segments. Under its Growth Track, selected early-stage startups receive EUR 100.000 funding to accelerate market uptake, coaching by Bayer executives, and tailored business acceleration clinics. Through the Advance Track framework, digital health companies are aligning for larger commercial deals.